BioLineRx has agreed to sell its rights to certain future royalties from its FDA-approved drug APHEXDA (motixafortide) to Soleus Capital for $5.6 million.
Under the agreement, Soleus will acquire BioLineRx’s 14.4% royalty interest in future APHEXDA net sales. BioLineRx will retain rights to potential commercial milestone payments under its existing licensing agreement with Ayrmid Pharma. The transaction is expected to close on or about Nov. 30.
The company plans to use the proceeds to support research and development, including its ongoing phase 1/2a clinical trial of GLIX1 for glioblastoma and other solid tumors. Funds will also support working capital and a partial loan repayment to BlackRock EMEA Venture and Growth Lending, eliminating a $4 million minimum cash balance requirement under the loan agreement.
APHEXDA is FDA-approved for stem cell mobilization in patients with multiple myeloma undergoing autologous stem cell transplantation.